Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Cash from Operations (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Cash from Operations for 12 consecutive years, with 8900000.0 as the latest value for Q1 2026.

  • For Q1 2026, Cash from Operations rose 17.98% year-over-year to 8900000.0; the TTM value through Mar 2026 reached 62908000.0, down 117.11%, while the annual FY2025 figure was 71500000.0, 129.9% down from the prior year.
  • Cash from Operations hit 8900000.0 in Q1 2026 for Crescent Biopharma, up from 26708000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 6974854.0 in Q2 2023 and bottomed at 26708000.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 11904170.77, with a median of 10508829.0 recorded in 2024.
  • Year-over-year, Cash from Operations fell 19.24% in 2022 and then surged 57.03% in 2023.
  • Crescent Biopharma's Cash from Operations stood at 7911569.0 in 2022, then grew by 3.75% to 7614997.0 in 2023, then crashed by 38.0% to 10508829.0 in 2024, then plummeted by 154.15% to 26708000.0 in 2025, then surged by 66.68% to 8900000.0 in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 8900000.0, 26708000.0, and 16449000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.